What is the recommended evaluation and management for a man presenting with hair thinning?

Evaluation and Management of Male Hair Thinning

Confirm the Diagnosis: Androgenetic Alopecia vs. Alopecia Areata

The first critical step is distinguishing androgenetic alopecia (male pattern baldness) from alopecia areata, because these conditions require completely different treatments. 1

Pattern Recognition

• Androgenetic alopecia presents with gradual thinning at the temples, vertex (crown), and mid-frontal scalp, while the occipital (back) and lateral (side) scalp hair remains preserved 1
• Use the Hamilton-Norwood classification to document the extent and pattern of hair loss 1
• Alopecia areata presents with discrete, patchy hair loss and exclamation-mark hairs (short broken hairs at patch margins visible on dermoscopy) 2
• If you see patchy loss rather than patterned thinning, you are dealing with alopecia areata, not androgenetic alopecia 1

When Laboratory Testing is Needed

• For typical androgenetic alopecia with characteristic pattern, no laboratory testing is required 2
• Order targeted labs only if the presentation is atypical or suggests underlying disease 2:
  • TSH and free T4 if thyroid symptoms are present 2
  • Serum ferritin (optimal ≥60 ng/mL for hair growth) if iron deficiency is suspected 2
  • Fungal culture only if scalp inflammation or scaling suggests tinea capitis 2
  • Scalp biopsy only if the diagnosis remains uncertain after clinical examination 2

Common pitfall: Ordering extensive autoimmune panels for straightforward androgenetic alopecia adds no value and should be avoided 2

---

First-Line Treatment for Androgenetic Alopecia

Initiate combination therapy with oral finasteride 1 mg daily plus topical minoxidil 5% solution 1 mL twice daily—these are the only FDA-approved treatments proven to halt progression and stimulate regrowth. 1

Finasteride

• Finasteride works by inhibiting 5-alpha reductase, blocking conversion of testosterone to dihydrotestosterone (DHT) 1
• Clinical improvement occurs in up to 66% of men treated for 2 years, effective for both frontal and vertex thinning 3
• Treatment must be continued indefinitely—stopping leads to return of hair loss within months 1, 4

Minoxidil

• Topical minoxidil 5% promotes hair growth through direct follicular stimulation 1
• Apply 1 mL to dry scalp twice daily, ensuring the medication reaches the scalp directly 4
• Results may appear as early as 2 months, but some men require at least 4 months of consistent use 4
• Initial shedding for up to 2 weeks is expected and indicates old hairs are being replaced by new growth 4
• Like finasteride, minoxidil must be continued indefinitely to maintain results 4

Critical counseling point: Both medications require lifelong use. Discontinuation results in reversal of all gains within months 1, 4, 3

---

Monitoring Treatment Response

Use standardized photographs comparing baseline to follow-up at 4–6 month intervals as the primary objective measure of treatment efficacy. 1

Assessment Tools

• Standardized before-and-after photographs taken under consistent lighting 1
• Patient satisfaction questionnaires to capture subjective improvement 1
• Terminal versus vellus hair ratio on dermoscopy (if available) 5

If no improvement is seen after 4 months of consistent twice-daily use, the patient is a non-responder and should discontinue minoxidil 4

---

Second-Line Treatment: Platelet-Rich Plasma (PRP)

For men with suboptimal response to finasteride and minoxidil after 6 months, add PRP injections as adjunctive therapy. 1

PRP Protocol

• Treatment phase: 3–5 sessions at 1-month intervals using 5–7 mL PRP per session 1, 2
• Injection technique: 90-degree angle, 2–4 mm depth, injections spaced 1 cm apart, dose 0.05–0.1 mL/cm² 2
• Maintenance phase: 1 session every 6 months after initial treatment 1, 2
• Use nonactivated PRP with platelet concentration of 1–1.5 million platelets per µL (31% greater improvement versus activated PRP) 5
• Apply pharmaceutical-grade topical anesthetic cream before injection due to significant pain 5

Expected Outcomes

• Combination therapy (finasteride + minoxidil + PRP) achieves 57% median increase in terminal hair density versus 48% with minoxidil alone at 32 weeks 5
• Maximum response typically achieved by 6 months 5

Common pitfall: Low platelet concentration, inadequate injection volume, or insufficient treatment frequency leads to PRP failure 5

---

Alternative and Adjunctive Options

Low-Level Laser Therapy (LLLT)

• FDA-cleared 655 nm laser devices used three times per week for 15–30 minutes at home 5
• Continuous indefinite use required to maintain regrowth 5
• Can be used as adjunctive therapy alongside finasteride and minoxidil 5

Emerging Treatments

• Oral dutasteride 0.5 mg induces better responses than finasteride, especially in the frontal area, though not FDA-approved for this indication 6
• Topical finasteride 0.25% daily offers efficacy with less systemic DHT suppression than oral formulation 6
• Oral minoxidil 2.5–5 mg daily shows effectiveness in clinical studies but is not FDA-approved for androgenetic alopecia; main adverse effect is hypertrichosis 6
• Platelet-rich fibrin (PRF) shows promise as a potentially superior alternative to PRP with lower cost and easier preparation 5

---

Hair Transplantation

Consider hair transplantation (follicular unit extraction) for men with inadequate response to medical therapy, especially when combined with PRP pre-treatment and follicle soaking. 1

• Surgical options provide permanent results for advanced hair loss 1
• Wigs provide immediate cosmetic benefit but rarely appear natural for men 7, 1

---

Management of Alopecia Areata (If Diagnosed Instead)

If the patient has patchy hair loss with exclamation-mark hairs, this is alopecia areata—not androgenetic alopecia—and requires entirely different treatment. 1

Limited Patchy Alopecia Areata (≤5 patches, each ≤3 cm)

• Watchful waiting is first-line: 34–50% experience spontaneous regrowth within one year without treatment 7, 2
• Counsel that regrowth cannot be expected within 3 months of any individual patch 2
• If treatment is desired: Intralesional triamcinolone acetonide 5–10 mg/mL (0.05–0.1 mL per injection) monthly produces regrowth in 62% of patients (Strength of recommendation B, Quality III) 7, 2

Extensive Alopecia Areata (>50% scalp involvement)

• Contact immunotherapy with diphenylcyclopropenone (DPCP) is the best-documented treatment but achieves response in <50% of patients and requires multiple hospital visits over months (Strength of recommendation B, Quality II-ii) 7, 2
• Wigs provide immediate cosmetic benefit and are often the most practical solution for extensive disease 7, 2

Treatments to Avoid in Alopecia Areata

• Potent topical corticosteroids lack convincing efficacy evidence 7, 2
• Systemic corticosteroids and PUVA have potentially serious adverse effects with inadequate efficacy evidence 7, 2
• Oral zinc and isoprinosine are ineffective in controlled trials 7, 2

Critical distinction: No treatment alters the long-term natural history of alopecia areata; interventions may induce temporary regrowth only 2

---

Key Pitfalls to Avoid

• Do not confuse trichotillomania with alopecia areata: Trichotillomania shows broken hairs firmly anchored in anagen phase, whereas alopecia areata displays exclamation-mark hairs 2
• Do not use corticosteroids for androgenetic alopecia—they are ineffective and indicated only for alopecia areata 1
• Do not delay effective treatment with unproven supplements like saw palmetto, as this may result in irreversible hair loss 1
• Individual genetic factors significantly influence response to all treatments; not all patients will respond 5